Redhill Biopharma
RDHL

Redhill Biopharma (RDHL) earnings history

Most recent quarter

Period end
Mar 31, 2023
EPS actual
−$1.25
Revenue
$3.6M
Reported
Jun 12, 2023

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q1 2023Jun 12, 2023$0.00−$1.25+0.00%$3.6MSEC
Q3 2022Nov 29, 2022−$10.00−$60.00−500.00%$17.6M
Q2 2022Invalid Date−$20.00−$20.00+0.00%$18.3M
Q1 2022Jun 23, 2022−$300.00−$30.00+90.00%$18.2M
Q4 2021Mar 17, 2022−$433.33−$500.00−15.38%$22.1M
Q3 2021Nov 30, 2021−$474.29−$500.00−5.42%$21.6M
Q2 2021Aug 26, 2021−$352.86−$600.00−70.04%$21.5M
Q1 2021May 27, 2021−$435.00−$500.00−14.94%$20.6M
Q4 2020Mar 18, 2021−$346.00−$650.00−87.86%$21.5M
Q3 2020Nov 12, 2020−$270.00−$500.00−85.19%$20.9M
Q2 2020Aug 13, 2020−$137.50−$400.00−190.91%$20.9M
Q1 2020May 27, 2020−$690.00−$500.00+27.54%$1.1M

Quarterly revenue

Q1 2020
$1.1M
Q2 2020
$20.9M
Q3 2020
$20.9M
Q4 2020
$21.5M
Q1 2021
$20.6M
Q2 2021
$21.5M
Q3 2021
$21.6M
Q4 2021
$22.1M
Q1 2022
$18.2M
Q2 2022
$18.3M
Q3 2022
$17.6M
Q1 2023
$3.6M

Frequently asked questions

  • When did Redhill Biopharma (RDHL) last report earnings?

    Redhill Biopharma last reported on Jun 12, 2023, covering fiscal Q1 2023.

  • Did RDHL beat earnings estimates?

    Redhill Biopharma reported EPS of −$1.25 for Q1 2023, in line with the $0.00 consensus estimate.

  • How much revenue did RDHL report last quarter?

    Redhill Biopharma reported $3.6M in revenue for Q1 2023.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.